Exelixis (EXEL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$59.01-0.20%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · EXEL
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | FY 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | — | 2,320.1 | 2,320.1 | 2,168.7 | 1,830.2 | 1,611.1 | 1,435.0 | 967.8 | 967.8 | 853.8 | 452.5 | 191.5 | 37.2 | 25.1 | 31.3 | 47.5 | 289.6 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | 452.5 | 191.5 | 37.2 | 25.1 | 31.3 | 47.5 | 289.6 |
| Cost of Revenues | — | 83.7 | 83.7 | 76.2 | 72.5 | 57.9 | 52.9 | 33.1 | 33.1 | 26.3 | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | — | 518.7 | 518.7 | 492.1 | 542.7 | 459.9 | 401.7 | 228.2 | 228.2 | 206.4 | 159.3 | 116.1 | 57.3 | 50.8 | 51.0 | — | — |
| R&D Expenses | — | 825.0 | 825.0 | 910.4 | 1,044.1 | 891.8 | 693.7 | 337.0 | 337.0 | 182.3 | 112.2 | 96.0 | 96.4 | 189.1 | 178.8 | 128.9 | 156.8 |
| Operating Income | — | 872.2 | 872.2 | 604.6 | 170.9 | 201.5 | 286.7 | 369.5 | 369.5 | 438.9 | 165.9 | (28.1) | (121.4) | (224.5) | (200.7) | (122.4) | 89.5 |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 8.7 | 33.1 | 40.7 | 41.4 | 38.8 | 24.8 | 16.3 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | 28.6 | 28.6 | 13.2 | (7.3) | (42.1) | (40.3) | (37.0) | (37.6) | (22.8) | — |
| Asset Writedown | — | 0.0 | — | 64.4 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | — | — | — | — | — | 130.8 | 398.1 | 398.1 | 452.1 | 158.6 | (70.2) | (161.7) | (261.5) | (244.9) | (147.5) | 77.0 |
| Income Tax Expense | — | 158.6 | 158.6 | 160.4 | 49.8 | 52.1 | 63.1 | 77.1 | 77.1 | (238.0) | 4.4 | 0.0 | 0.1 | (0.2) | (0.1) | 0.1 | 1.3 |
| Earnings from Continuing Operations | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (244.8) | (147.6) | 75.7 |
| Net Income | |||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (4.3) |
| Net Income | — | 782.6 | 782.6 | 521.3 | 207.8 | 182.3 | 231.1 | 321.0 | 321.0 | 690.1 | 154.2 | (70.2) | (161.7) | (261.3) | (238.2) | (145.3) | 75.7 |
| Per Share | |||||||||||||||||
| Basic EPS | — | 2.88 | 2.88 | 1.80 | 0.65 | 0.57 | 0.73 | 1.06 | 1.06 | 2.32 | 0.52 | — | — | — | (1.33) | (0.92) | 0.60 |
| Diluted EPS | — | 2.78 | 2.78 | 1.76 | 0.65 | 0.56 | 0.72 | 1.02 | 1.02 | 2.21 | 0.49 | — | — | — | (1.33) | (0.92) | 0.58 |
| Basic Weighted Avg Shares | 250.8 | 271.6 | 271.6 | 290.0 | 318.2 | 321.5 | 314.9 | 302.6 | 302.6 | 297.9 | 293.6 | — | — | — | 184.1 | 160.1 | 126.0 |
| Diluted Weighted Avg Shares | 259.7 | 281.9 | 281.9 | 296.1 | 321.5 | 324.6 | 322.4 | 315.0 | 315.0 | 312.8 | 312.0 | — | — | — | 184.1 | 160.1 | 130.5 |
| Supplemental | |||||||||||||||||
| EBITDA | — | 901.2 | 901.2 | 633.4 | 196.6 | 222.4 | 300.3 | 377.8 | 377.8 | 443.8 | 167.1 | (27.1) | (120.0) | (222.1) | (197.6) | (116.9) | 96.4 |
| EBIT | — | 872.2 | 872.2 | 604.6 | 170.9 | 201.5 | 286.7 | 369.5 | 369.5 | 438.9 | 165.9 | (28.1) | (121.4) | (224.5) | (200.7) | (122.4) | 89.5 |
| Effective Tax Rate | — | — | — | — | — | — | 48.2% | 19.4% | 19.4% | -52.6% | 2.7% | 0.0% | -0.0% | 0.1% | 0.0% | -0.1% | 1.7% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.